Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents
Br J Haematol
.
2023 May;201(3):564-567.
doi: 10.1111/bjh.18701.
Epub 2023 Feb 22.
Authors
Francesca R Mauro
1
,
Andrea Visentin
2
,
Diana Giannarelli
3
,
Maria C Molinari
1
,
Giulia Proietti
1
,
Marco Petrella
2
,
Francesco Angotzi
2
,
Sara Pepe
1
,
Livio Trentin
2
,
Silvia Baroncelli
4
,
Emanuela Giombini
5
,
Silvia Meschi
5
,
Fabrizio Maggi
5
,
Daniele Focosi
6
Affiliations
1
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
2
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy.
3
Design and Analysis of Clinical Trials Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
4
National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
5
Laboratory of Virology, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), Rome, Italy.
6
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
PMID:
36810731
DOI:
10.1111/bjh.18701
No abstract available
Publication types
Letter
MeSH terms
Antineoplastic Agents* / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Pre-Exposure Prophylaxis*
Substances
tixagevimab
cilgavimab
Antineoplastic Agents